Cease Omega-3 Fatty Acid Intake in Cases of Atrial Fibrillation Risk

Об этом видео:Cease Omega-3 Fatty Acid Intake in Cases of Atrial Fibrillation Risk
The Pharmacovigilance Risk Assessment Committee of the European Medicines Agency has noted that atrial fibrillation can be a common side effect of medicinal products containing omega-3 fatty acids. In the event that atrial fibrillation occurs, it is advised to permanently discontinue the use of such medications based on their recommendation. Omega-3 fatty acids are utilized to address hypertriglyceridemia and, until recently, were frequently recommended as an adjunctive treatment for atrial fibrillation. However, experts from the Committee have identified a dose-dependent increase in the risk of atrial fibrillation in patients with cardiovascular diseases or cardiovascular risk factors who are undergoing treatment with omega-3 fatty acids, as compared to those treated with a placebo. The highest observed risk was associated with a dosage of 4 g/day. Therefore, if your patient is at risk of atrial fibrillation, even if episodes have not been formally recorded, the use of such medications should not be advised. If they have already been initiated, they should be permanently discontinued.

Видео Cease Omega-3 Fatty Acid Intake in Cases of Atrial Fibrillation Risk канала Яблучанський М.І., доктор медичних наук, професор